Core Insights - The year 2025 marks a "watershed" moment for China's flow cytometry market, driven by geopolitical uncertainties and a shift towards "deep localization" as a survival necessity for companies [1][2] Market Overview - The total bid amount for flow cytometers in 2025 reached 641,297,934 yuan, with a total of 486 units awarded [3] - BD retained the top position in bid amounts, while Beckman Coulter surpassed BD in bid quantity, indicating a significant market reshuffle influenced by geopolitical factors and localization strategies [2][5] Competitive Landscape - Beckman Coulter emerged as the top bidder in terms of quantity, while BD maintained the highest bid amount, with the gap in bid amounts between the two companies narrowing from nearly 20% in 2024 to less than 3% in 2025 [10] - The top three companies accounted for over 60% of the total bid amount, while the top ten accounted for over 90% [3][5] Product Performance - Beckman Coulter dominated the top ten bid models, securing the first, second, fifth, and sixth positions with models such as DxFLEX and CytoFLEX [7][9] - The highest bid price for a flow cytometer was 11,486,000 yuan for Standard BioTool's Hyperion XTi, while the lowest was under 50,000 yuan for a model from Rescale [11] User Demand and Market Trends - Hospitals accounted for approximately 48.83% of the bid amount and 48.03% of the bid quantity, with a notable increase in demand from disease control centers, particularly due to a large order from the Xinjiang CDC [15] - The market is witnessing a shift towards lower-tier cities, with significant growth expected in the southwest and central regions of China [20] Regional Insights - The top regions for flow cytometer bids in 2025 included Guangdong (11.9%), Beijing (10.8%), and Shanghai (9.9%), with increasing demand in the southwest and central regions [17][19]

Core Viewpoint - The first Flow Cytometer Industrialization Development Forum was successfully held in Shanghai, focusing on technological advancements and the current state of the flow cytometry industry, discussing new trends in industry development [1][2]. Group 1: Forum Overview - The forum attracted over 1,800 participants from various sectors, including government leaders, experts, instrument manufacturers, testing institutions, and investors, marking a record scale for the event [2]. - The forum was a highlight of the 18th Annual Conference of China Scientific Instruments (ACCSI 2025), which aims to promote effective communication among various stakeholders in the scientific instrument industry [31]. Group 2: Industry Development - The flow cytometry industry has made significant progress in market size, competitive landscape, technological innovation, and application field expansion, moving beyond traditional research and clinical testing to new areas such as bioengineering, environmental science, and food science [4][5]. - The emergence of various popular flow cytometry technologies is driving the industry into a new round of transformation, raising questions about achieving a win-win situation between local brand development and the localization of imported brands [5]. Group 3: Key Presentations - Keynote presentations were delivered by industry experts, including advancements in nano-flow cytometry technology for extracellular vesicle detection, which allows for high-resolution analysis of particles as small as 40 nm [10][11]. - The development of next-generation high-parameter flow cytometers represents a significant technological advancement, providing high-quality biological data to address key societal challenges in health, food, energy, and environment [12][13]. - The challenges and necessary innovations in the flow cytometry antibody industry were discussed, highlighting the success of companies like BioLegend, which achieved over $400 million in sales [14][15]. Group 4: Roundtable Discussion - A roundtable discussion featured nearly 50 experts discussing the opportunities and challenges in the flow cytometry industry, including the impact of AI and machine learning on future developments [21][23]. - The discussion emphasized the importance of product application in real-world scenarios and the potential for domestic brands to replace imported ones while addressing quality and functionality differences [23].

导读： 大阪大学研发出基于时间延迟积分技术的高速Raman流式细胞仪，实现无需荧光标记的高通量细胞检测，突破传统技术瓶颈。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 长期以来，拉曼流式细胞术以其"非标记"（无需荧光染料即可获得细胞内部化学信息）特性，在生物医学领域备受关注。然而，由于拉曼散射 信号本身极其微弱，导致该技术在细胞检测通量方面远远落后于传统荧光流式细胞仪，限制了其在大规模筛查和实时分析中的应用。近日，日 本大阪大学的研究团队成功研发出一种基于时间延迟积分（Time De l a y a n d I n t e g r a ti o n，简称TDI）技术的高速拉曼流式细胞仪。这种新型 流式细胞分析系统，可以在无荧光标记的前提下，实现对流动细胞化学成分的高通量检测。该成果发表在2 0 2 5年4月的 《Opti c a》期刊，题目 为 Raman fl ow c y t ome t r y using time -de l a y int e g r a ti on 。 论文链接：h t t p s: / / d o ...